Romvimza Side Effects

Generic name: vimseltinib

Note: This document provides detailed information about Romvimza.

Applies to vimseltinib: oral capsules Side Effects associated with vimseltinib. Some dosage forms listed on this page may not apply specifically to the brand name Romvimza.

Applies to vimseltinib: oral capsules.

Side effects include:

Most common adverse effects (≥20%): Increased AST concentrations, increased ALT concentrations, periorbital edema, fatigue, rash, increased cholesterol, peripheral edema, facial edema, decreased neutrophils, decreased leukocytes, pruritus.

For healthcare professionals

Applies to vimseltinib: oral capsule.

General adverse events

The most common adverse reactions included increased AST, periorbital edema, fatigue, rash, increased cholesterol, peripheral edema, face edema, decreased neutrophils, decreased leukocytes, pruritus, and increased ALT.^[Ref]

Cardiovascular

• Very common (10% or more): Hypertension (up to 17%)

Dermatologic

• Very common (10% or more): Rash (up to 47%), pruritus (up to 29%)
• Common (1% to 10%): Subcutaneous abscess, cellulitis

Hematologic

• Very common (10% or more): Decreased neutrophils (up to 31%), decreased leukocytes (up to 29%)

Hepatic

• Very common (10% or more): Increased AST (up to 92%), increased ALT (up to 24%)

During clinical trials, grade 3 increases in AST and ALT were reported in 2% and 1% of patients, respectively. Dose interruptions and reductions due to increased AST/ALT occurred in 2% and 1% of patients, respectively; at least 1 patient discontinued therapy due to grade 3 increased AST.

Musculoskeletal

• Common (1% to 10%): Increased creatine phosphokinase

Nervous system

• Very common (10% or more): Neuropathy (up to 12%)

Ocular

• Very common (10% or more): Periorbital edema (up to 60%), increased lacrimation (up to 12%), dry eye (up to 10%)
• Common (1% to 10%): Blurred vision

Other

• Very common (10% or more): Fatigue (up to 59%), increased cholesterol (up to 43%), peripheral edema (up to 33%), face edema (up to 31%), increased alkaline phosphatase (up to 14%), increased magnesium (up to 13%), decreased calcium (up to 13%)

Renal

• Very common (10% or more): Increased creatinine (up to 17%)

See also:

Further information

Romvimza side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer